0001529224-22-000001.txt : 20220920 0001529224-22-000001.hdr.sgml : 20220920 20220920115018 ACCESSION NUMBER: 0001529224-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220920 DATE AS OF CHANGE: 20220920 EFFECTIVENESS DATE: 20220920 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GeneCentric Therapeutics, Inc. CENTRAL INDEX KEY: 0001529224 IRS NUMBER: 452540158 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-459294 FILM NUMBER: 221252641 BUSINESS ADDRESS: STREET 1: 100 CAPITOLA DRIVE STREET 2: SUITE 275 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: (919) 973-6544 MAIL ADDRESS: STREET 1: 100 CAPITOLA DRIVE STREET 2: SUITE 275 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: GeneCentric Diagnostics, Inc. DATE OF NAME CHANGE: 20110902 D 1 primary_doc.xml X0708 D LIVE 0001529224 GeneCentric Therapeutics, Inc. 100 CAPITOLA DRIVE SUITE 275 DURHAM NC NORTH CAROLINA 27713 (919) 973-6544 DELAWARE GeneCentric Diagnostics, Inc. Corporation true MICHAEL MILBURN c/o GeneCentric Therapeutics, Inc. 100 Capitola Dr, Ste 275 Durham NC NORTH CAROLINA 27713 Executive Officer Director CLAY THORP c/o GeneCentric Therapeutics, Inc. 100 Capitola Dr, Ste 275 Durham NC NORTH CAROLINA 27713 Director ARNOLD LEVINE c/o GeneCentric Therapeutics, Inc. 100 Capitola Dr, Ste 275 Durham NC NORTH CAROLINA 27713 Director MYLA LAI-GOLDMAN c/o GeneCentric Therapeutics, Inc. 100 Capitola Dr, Ste 275 Durham NC NORTH CAROLINA 27713 Director ELLEN LUBMAN c/o GeneCentric Therapeutics, Inc. 100 Capitola Dr, Ste 275 Durham NC NORTH CAROLINA 27713 Director CHARLES PEROU c/o GeneCentric Therapeutics, Inc. 100 Capitola Dr, Ste 275 Durham NC NORTH CAROLINA 27713 Director Biotechnology Decline to Disclose 06b false 2022-09-08 false true false 0 3500000 2500000 1000000 false 1 0 0 0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. false GeneCentric Therapeutics, Inc. /s/ Michael Milburn Michael Milburn, PhD CEO 2022-09-20